WO2005063250A1 - 好中球増多抑制剤 - Google Patents
好中球増多抑制剤 Download PDFInfo
- Publication number
- WO2005063250A1 WO2005063250A1 PCT/JP2004/019199 JP2004019199W WO2005063250A1 WO 2005063250 A1 WO2005063250 A1 WO 2005063250A1 JP 2004019199 W JP2004019199 W JP 2004019199W WO 2005063250 A1 WO2005063250 A1 WO 2005063250A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neutrophilia
- hydrogen atom
- pyridazinone
- formula
- carbon atoms
- Prior art date
Links
- 206010029379 Neutrophilia Diseases 0.000 title claims abstract description 30
- 239000003112 inhibitor Substances 0.000 title claims abstract description 20
- -1 3(2H)-pyridazinone compound Chemical class 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 125000005843 halogen group Chemical group 0.000 claims abstract description 17
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 claims description 3
- YJMYSLFFZJUXOA-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 YJMYSLFFZJUXOA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 5
- 206010006458 Bronchitis chronic Diseases 0.000 abstract description 2
- 208000027932 Collagen disease Diseases 0.000 abstract description 2
- 208000014311 Cushing syndrome Diseases 0.000 abstract description 2
- 206010014561 Emphysema Diseases 0.000 abstract description 2
- 201000005569 Gout Diseases 0.000 abstract description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract description 2
- 206010006451 bronchitis Diseases 0.000 abstract description 2
- 208000007451 chronic bronchitis Diseases 0.000 abstract description 2
- 206010028537 myelofibrosis Diseases 0.000 abstract description 2
- 208000037244 polycythemia vera Diseases 0.000 abstract description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract description 2
- 208000023504 respiratory system disease Diseases 0.000 abstract description 2
- 150000003431 steroids Chemical class 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 description 14
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 9
- 229920000609 methyl cellulose Polymers 0.000 description 9
- 239000001923 methylcellulose Substances 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000779 smoke Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004816 2,2-dimethylethylene group Chemical group [H]C([H])([H])C([*:2])(C([H])([H])[H])C([H])([H])[*:1] 0.000 description 1
- 125000004813 2-ethylethylene group Chemical group [H]C([H])([H])C([H])([H])C([H])([*:2])C([H])([H])[*:1] 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- HZVJNIUTIWSMAC-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)-3-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1C(O)CCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 HZVJNIUTIWSMAC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229920001007 Nylon 4 Polymers 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical class OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N iso-butene Natural products CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- DWLAVVBOGOXHNH-UHFFFAOYSA-L magnesium;prop-2-enoate Chemical compound [Mg+2].[O-]C(=O)C=C.[O-]C(=O)C=C DWLAVVBOGOXHNH-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- GTLACDSXYULKMZ-UHFFFAOYSA-N pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to a neutrophilia inhibitor comprising a pyridazinone compound or a pharmacologically acceptable salt thereof as an active ingredient.
- a highly safe drug that specifically reduces neutrophilia is expected to be a preventive or therapeutic drug for some diseases for which there are currently very few medically useful drugs.
- diseases for which neutrophilia is expected to be applied are those in which the number of neutrophils abnormally increases.
- Specific examples include acute infections (bacterial infections, fungal infections, spirochetes, parasites, rickettsia, viruses), collagen diseases (rheumatoid arthritis, Wegener's granulomatosis, Behcet's disease), chronic obstructive Onset and progression of conditions such as pulmonary disease (COPD), chronic bronchitis, emphysema, peripheral airway disease, gout, Cushing's syndrome, myelofibrosis, neoplastic neutrophilia, polycythemia vera, and steroid administration A group of diseases involving neutrophils is listed.
- COPD pulmonary disease
- COPD chronic bronchitis
- emphysema peripheral airway disease
- gout Cushing's syndrome
- myelofibrosis myelofibrosis
- neoplastic neutrophilia polycythemia vera
- steroid administration A group of diseases involving neutrophils is listed.
- Pyridazinone compounds or salts thereof have excellent platelet aggregation inhibitory action, cardiotonic action, vasodilatory action, anti-SRS-A (Slow Reacting Substances of Anaphylaxis) action, thromboxane A2 synthase inhibitory action, and treatment of spinal canal stenosis It is known to have an action, a treatment action for erectile dysfunction, an angiogenesis-promoting action, an angiogenesis-enhancing action, and the like, and is a drug expected as an antiplatelet agent or the like (for example, see Patent Documents 116).
- Patent Document 1 Japanese Patent Publication No. 7-107055
- Patent Document 2 JP-A-7-252237
- Patent Document 3 JP-A-7-285869
- Patent Document 6 WO00Z33845
- An object of the present invention is to provide an excellent neutrophilia inhibitor.
- the present inventors have conducted various studies and found that the pyridazinone compound represented by the following formula (I) or a pharmacologically acceptable salt thereof has an excellent inhibitory effect on neutrophilia. And found that the present invention was completed.
- the present invention is characterized by having the following gist.
- a neutrophilia inhibitor comprising a 3 (2H) -pyridazinone compound represented by the formula (I) or a pharmacologically acceptable salt thereof.
- R ⁇ R 2 and R 3 are each independently a hydrogen atom or an alkyl group having 16 carbon atoms
- X is a halogen atom, cyano or a hydrogen atom
- Y is a halogen atom, trifluoromethyl
- A is substituted with a hydroxyl group for a hydrogen atom, and it represents alkylene having 118 carbon atoms.
- R 1 and R 2 are hydrogen atoms
- R 3 is a hydrogen atom or an alkyl group having 14 carbon atoms
- X is a halogen atom
- Y is a halogen atom or a hydrogen atom
- A is a hydroxyl group.
- the neutrophilia inhibitor according to the above (1) which is an alkylene having 15 to 15 carbon atoms which may be substituted.
- the neutrophilia inhibitor according to any one of (1) to (4) above which is an agent for preventing or treating chronic obstructive pulmonary disease.
- neutrophilia inhibitor of the present invention in formula (I), preferably, R 1 and R 2 are hydrogen atom, R 3 is a hydrogen atom or an alkyl group having a carbon number of 1 one 4, X Is a halogen atom, Y is a halogen atom or a hydrogen atom, and A is a hydroxyl group, and may be a pyridazinone derivative or a pharmacologically acceptable salt thereof, which is an alkylene having 15 to 15 carbon atoms. It is preferred that there be.
- neutrophilia inhibitor of the pyridazinone conjugate of the present invention represented by the formula (I)
- particularly preferred is, for example, 4bromo-6- [3- (4-chlorophene- L) propoxy] -5- (3-pyridylmethylamino) -3 (2H) -pyridazinone or 4-bromo-6- [3- (4-chlorophenol) -3-hydroxypropoxy] -5- (3- Pyridylmethylamino) —3 (2H) pyridazinone.
- the invention's effect is, for example, 4bromo-6- [3- (4-chlorophene- L) propoxy] -5- (3-pyridylmethylamino) -3 (2H) -pyridazinone or 4-bromo-6- [3- (4-chlorophenol) -3-hydroxypropoxy] -5- (3- Pyridylmethylamino) —3 (2H) pyridazinone.
- the present invention provides a novel neutrophilia inhibitor comprising the pyridazinone compound (I) or a pharmacologically acceptable salt thereof.
- FIG. 1 shows the results of Test Example 1.
- the alkyl group having 16 carbon atoms in R 2 and R 3 may be linear or branched. Specific examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, hexyl and the like.
- R 2 each include a hydrogen atom
- preferred R 3 includes a hydrogen atom and an alkyl group having 14 to 14 carbon atoms.
- alkyl group having 14 carbon atoms for R 3 include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl and the like. More preferred R 3 is a hydrogen atom.
- the halogen atom in X and Y means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
- Preferred X includes a halogen atom
- preferred Y includes a halogen atom and a hydrogen atom.
- the alkylene having 18 carbon atoms which may be substituted with a hydroxyl group in A may be linear or branched, and specifically, methylene, ethylene, propylene, butylene, pentylene, Xylene, heptylene, otaylene, 2,2-dimethylethylene, 2,2-ethylethylene, 2,2-di-propylethylene, hydroxymethylene, 1-hydroxyethylene, 2-hydroxyethylene, 3-hydroxypropylene, etc. No.
- A is an alkylene having 15 to 15 carbon atoms, which is substituted with a hydroxyl group.
- the bonding position of the methylene group and the pyridine ring is not particularly limited, but is preferably 3-position to the nitrogen atom of the pyridin ring.
- Y may be substituted at any position on the benzene ring, but is preferably at the 4-position.
- R 1 and R 2 are a hydrogen atom
- R 3 is a hydrogen atom or an alkyl having 14 to 14 carbons
- X is a halogen atom
- Y is a halogen atom or a hydrogen atom
- A is a hydroxyl group
- a pyridazinone compound which is an alkylene having 1 to 5 carbon atoms is preferred! /.
- Preferred compounds are 4-bromo-6- [3- (4-chlorophenol) propoxy] -5- (3-pyridylmethylamino) -3 (2H) pyridazinone, 4-bromo-6- [3- (4-hydroxypropoxy) -3-hydroxypropoxy] -5- (3-pyridylmethylamino) -3 (2H) pyridazinone and its pharmacologically acceptable salts.
- the pharmacologically acceptable salt of the pyridazinone conjugate (I) includes, for example, a salt with an inorganic acid (hydrochloride, hydrobromide, phosphate, Sulfate, etc.), and salts with organic acids (acetate, succinate, maleate, fumarate, malate, tartrate, etc.). These salts can be produced from the pyridazinone compound (I) by known means.
- the pyridazinone compound (I) and the pharmacologically acceptable salt thereof in the present invention also include stereoisomers and optical isomers.
- These pyridazinone conjugates (I) and pharmacologically acceptable salts thereof are known compounds and are known to have low toxicity.
- the compound is disclosed in, for example, Japanese Patent Publication No. 7-107055, U.S. Pat.No. 5,314,883, European Patent No. 482208, Japanese Patent Application Laid-Open No. 7-252237, U.S. Pat.No. 5,750,523, and European Patent No. 742211. And the like.
- the pyridazinone compound (I) and the pharmacologically acceptable salt thereof of the present invention are excellent in mammals such as humans, dogs, rabbits, tigers, rabbits, mice and rats. Has the effect of suppressing neutrophilia.
- the dose of the pyridazinone compound (I) or a pharmacologically acceptable salt thereof according to the present invention may be appropriately selected depending on the age, weight, and degree of symptoms of the patient. Usually, for human adults, 0.001 mg-5 gZ, preferably 0.005-100 mgZ, is administered once or several times.
- the administration form of the pyridazinone conjugate (I) or a pharmaceutically acceptable salt thereof according to the present invention includes injections (subcutaneous, intravenous, intramuscular, intraperitoneal injection), ointments, suppositories, and the like.
- Parenteral administration such as tablets, capsules, granules, pills, powders, troches, tutuples, syrups, solutions, emulsions, suspensions, etc. Oral administration can be mentioned. Oral administration is preferred.
- the pyridazinone compound (I) or a pharmaceutically acceptable salt thereof according to the present invention is formulated for administration by conventional pharmaceutical means.
- tablets, capsules, granules, pills, powders, troches and chewable tablets for oral administration include excipients (eg, sucrose, lactose, glucose, starch, mannitol, etc.), binders (eg, syrup) , Gum arabic, gelatin, sorbit, tragacanth, methylcellulose, polypyrrolidone, etc.), disintegrants (eg, starch, carboxymethylcellulose or its calcium salt, microcrystalline cellulose, polyethylene glycol, etc.), lubricants (eg, talc, stearin) It is prepared by known means using magnesium acrylate, calcium stearate, silica, etc.), lubricants (eg, sodium laurate, glycerol, etc.), etc.
- excipients eg, sucrose, lactose, glucose, starch, mannitol, etc.
- binders eg, syrup
- Gum arabic e.
- gelatin sorbit
- the dissolution and absorption can be improved by adding an organic acid.
- organic acid include citric acid, succinic acid, maleic acid, fumaric acid, lingic acid, tartaric acid and the like.
- injections, aerosols, syrups, solutions, emulsions, suspensions, eye drops, nasal drops, and the like include solvents for the active ingredient (eg, water, ethyl alcohol, isopropyl alcohol, propylene glycol, 1,3-butylene glycol, polyethylene glycol, etc.), surfactants (for example, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene ether of hydrogenated castor oil, lecithin, etc.)
- Turbidity agents eg, carboxymethyl sodium salt, cellulose derivatives such as methylcellulose, natural gums such as tragacanth, gum arabic, etc.
- preservatives eg, esters of paraoxybenzoic acid, benzalco-pam, sorbate, etc.
- Suppositories are prepared by known means using, for example, cocoa butter, polyethylene glycol, etc.
- ointment which is a transdermal absorption preparation
- white petrolatum liquid paraffin, higher alcohol, macrogol ointment, hydrophilic ointment, aqueous gel base and the like are used.
- Wistar male rats weighing 100-200 g are placed in a transparent plastic box (W30XH30XD30cm) for inhalation of small animals, and lipopolysaccharide solution (LPS E) is treated with an ultrasonic nebulizer (TUR-3200, manufactured by Nihon Kohden).
- LPS E lipopolysaccharide solution
- TUR-3200 ultrasonic nebulizer
- Compound A was suspended in 0.5% methylcellulose (MC), and each was suspended in lmg / 4mL / kg,
- 3mgZ4mLZkg and 10mgZ4mLZkg were orally administered in the vehicle group, 0.5% MC 2mLZkg 30 minutes before inhalation of lipopolysaccharide.
- the untreated group was orally administered 2 mL Zkg of 0.5% MC 30 minutes before inhalation of physiological saline. The tests were performed in 6 cases per group.
- bronchoalveolar lavage fluid was collected. That is, after intraperitoneal injection of urethane into the rat, the trachea was incised into the airway through the trachea-Eure attached to the trachea and instilled into the airway twice and washed twice. This washing was performed twice, and 10 mL of bronchoalveolar lavage fluid was collected. The collected bronchoalveolar lavage fluid was immediately centrifuged at 4 ° C for 10 minutes at 1471 mZs2, and the sedimented cells were suspended in 0.5 mL of 0.2% saline.After 1 minute, 1.6% saline was added. . The total leukocyte count of the suspension was measured using a multi-item automatic hemacytometer, and this was taken as the total leukocyte count.
- the 100 L were centrifuged 400 rpm, 4 min at room temperature using a current cell centrifuge (manufactured by Sir Mo 'Shandon Inc.), smear Was prepared.
- the specimen was stained with Diff Quick (Kokusai Reagent Co., Ltd.), and about 500 monocytes, eosinophils and neutrophils were counted under an inverted microscope (X400).
- Each leukocyte count was calculated from the ratio to the total leukocyte count according to the following equation.
- Each white blood cell count total white blood cell count x percentage of each white blood cell (count of each white blood cell Z total count of cells) SAS preclinical package V5 was used for statistical analysis software.
- the analysis of one-factor experimental data analysis of two groups, t-test) was used for the significant difference test between the negative control group and the lipopolysaccharide solvent group, and the one-factor experiment was used for the significant difference test between the control group and the drug-treated group.
- data analysis “parametric Dunnett-type multiple comparison test” it was judged to be significant when p ⁇ 0.05 (two-sided).
- Cigarette smoke is applied to a Hartley-type guinea pig weighing 350-450 g, using a smoke exposure device and a shampoo channo ⁇ (Flow-pasttype nose-only inhalation cnamber, Muenster: ⁇ ), 1 hour a day, 1 week Exposure was for 5 days and 3 weeks.
- the compound was suspended in 0.5% methylcellulose (MC) and orally administered with 10 mgZ2mLZkg.
- MC2mLZkg was orally administered 15 to 45 minutes before cigarette smoke exposure.
- 2 mLZkg of 0.5% MC was orally administered 15 to 45 minutes before air exposure.
- the evaluation was performed in four to six rows per group.
- Compound A inhibited neutrophil growth by 73% and inhibited airway resistance by 100%. It is clear that Compound A has an effect on respiratory dysfunction associated with neutrophilic inflammation due to cigarette smoke exposure in guinea pigs.
- Compound A (10 g), lactose (20 g), microcrystalline cellulose (10 g), and magnesium stearate (41 g) were mixed in a conventional manner, and then filled into a gelatin capsule to give a capsule containing 50 mg of compound A in one capsule. .
- the following component (A) is mixed, and the resulting mixture is charged into a container equipped with a valve.
- the following propellant (B) is added at 20 ° C to about 2.46 to 2.81 mgZcm 2 gauge pressure. Pressurized from the valve nozzle to make an aerosol suspension.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/584,222 US20070117806A1 (en) | 2003-12-26 | 2004-12-22 | Neutrophilia inhibitor |
CN2004800381582A CN1897952B (zh) | 2003-12-26 | 2004-12-22 | 中性白细胞增多抑制剂 |
AU2004308806A AU2004308806B9 (en) | 2003-12-26 | 2004-12-22 | Neutrophilia inhibitor |
JP2005516599A JP4688681B2 (ja) | 2003-12-26 | 2004-12-22 | 好中球増多抑制剤 |
CA2549672A CA2549672C (en) | 2003-12-26 | 2004-12-22 | Antineutrophilia agent using 3(2h)-pyridazinone compounds |
KR1020097027323A KR101293350B1 (ko) | 2003-12-26 | 2004-12-22 | 호중구증다 억제제 |
BRPI0417200-0A BRPI0417200A (pt) | 2003-12-26 | 2004-12-22 | agente antineutrofilia |
EP04807556A EP1698339A4 (en) | 2003-12-26 | 2004-12-22 | INHIBITOR OF NEUTROPHILY |
IL176473A IL176473A (en) | 2003-12-26 | 2006-06-21 | 3 (2h) - pyridazinone for use as a neutrophil inhibitor |
HK07104941.5A HK1098378A1 (en) | 2003-12-26 | 2007-05-09 | Neutrophilia inhibitor |
US12/188,638 US20080306080A1 (en) | 2003-12-26 | 2008-08-08 | Neutrophilia inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-433747 | 2003-12-26 | ||
JP2003433747 | 2003-12-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/188,638 Division US20080306080A1 (en) | 2003-12-26 | 2008-08-08 | Neutrophilia inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005063250A1 true WO2005063250A1 (ja) | 2005-07-14 |
Family
ID=34736527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/019199 WO2005063250A1 (ja) | 2003-12-26 | 2004-12-22 | 好中球増多抑制剤 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20070117806A1 (ja) |
EP (1) | EP1698339A4 (ja) |
JP (1) | JP4688681B2 (ja) |
KR (2) | KR101293350B1 (ja) |
CN (1) | CN1897952B (ja) |
AU (1) | AU2004308806B9 (ja) |
BR (1) | BRPI0417200A (ja) |
CA (1) | CA2549672C (ja) |
HK (1) | HK1098378A1 (ja) |
IL (1) | IL176473A (ja) |
RU (1) | RU2356555C2 (ja) |
TW (1) | TW200522962A (ja) |
WO (1) | WO2005063250A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101537006B (zh) * | 2008-03-18 | 2012-06-06 | 中国科学院上海药物研究所 | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 |
CN102133217B (zh) * | 2010-01-27 | 2013-07-24 | 中国科学院上海药物研究所 | 一类以n为桥键的哒嗪酮类化合物在制备抗肿瘤的药物中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000033845A1 (fr) * | 1998-12-07 | 2000-06-15 | Nissan Chemical Industries, Ltd. | Agent therapeutique pour le traitement de la dyserection |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07107055B1 (ja) * | 1990-04-25 | 1995-11-15 | ||
IL112695A (en) * | 1994-02-22 | 1999-04-11 | Green Cross Corp | Pharmaceutical compositions containing pyridazinone derivatives |
ATE307584T1 (de) * | 1997-08-28 | 2005-11-15 | Nissan Chemical Ind Ltd | Mittel zur förderung und verstärkung der neovaskularisierung |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
DK1123704T3 (da) * | 1998-09-01 | 2004-11-01 | Nissan Chemical Ind Ltd | Midler til spinalstenose |
JP2001131088A (ja) * | 1999-11-02 | 2001-05-15 | Kyurin:Kk | シンドロームx症候群治療剤 |
-
2004
- 2004-12-22 EP EP04807556A patent/EP1698339A4/en not_active Withdrawn
- 2004-12-22 KR KR1020097027323A patent/KR101293350B1/ko not_active IP Right Cessation
- 2004-12-22 RU RU2006127040/15A patent/RU2356555C2/ru not_active IP Right Cessation
- 2004-12-22 CN CN2004800381582A patent/CN1897952B/zh not_active Expired - Fee Related
- 2004-12-22 BR BRPI0417200-0A patent/BRPI0417200A/pt not_active Application Discontinuation
- 2004-12-22 CA CA2549672A patent/CA2549672C/en not_active Expired - Fee Related
- 2004-12-22 JP JP2005516599A patent/JP4688681B2/ja not_active Expired - Fee Related
- 2004-12-22 AU AU2004308806A patent/AU2004308806B9/en not_active Ceased
- 2004-12-22 KR KR1020067012723A patent/KR20060125816A/ko not_active Application Discontinuation
- 2004-12-22 US US10/584,222 patent/US20070117806A1/en not_active Abandoned
- 2004-12-22 WO PCT/JP2004/019199 patent/WO2005063250A1/ja active Application Filing
- 2004-12-24 TW TW093140627A patent/TW200522962A/zh not_active IP Right Cessation
-
2006
- 2006-06-21 IL IL176473A patent/IL176473A/en not_active IP Right Cessation
-
2007
- 2007-05-09 HK HK07104941.5A patent/HK1098378A1/xx not_active IP Right Cessation
-
2008
- 2008-08-08 US US12/188,638 patent/US20080306080A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000033845A1 (fr) * | 1998-12-07 | 2000-06-15 | Nissan Chemical Industries, Ltd. | Agent therapeutique pour le traitement de la dyserection |
Non-Patent Citations (1)
Title |
---|
ELWOOD W. ET AL.: "Inhibition of allegren-induced lungeosinophila by type-III and combined type-II and IV-selective phosphodiesterase inhibitors in Brown-Noeway rats", INFLAMM. RES., vol. 44, 1995, pages 83 - 86, XP008112791 * |
Also Published As
Publication number | Publication date |
---|---|
CA2549672A1 (en) | 2005-07-14 |
US20070117806A1 (en) | 2007-05-24 |
CN1897952A (zh) | 2007-01-17 |
AU2004308806B9 (en) | 2010-01-28 |
EP1698339A1 (en) | 2006-09-06 |
KR20060125816A (ko) | 2006-12-06 |
KR101293350B1 (ko) | 2013-08-05 |
CN1897952B (zh) | 2010-12-08 |
BRPI0417200A (pt) | 2007-02-06 |
TWI341729B (ja) | 2011-05-11 |
KR20100019542A (ko) | 2010-02-18 |
RU2006127040A (ru) | 2008-02-10 |
IL176473A (en) | 2013-06-27 |
AU2004308806B2 (en) | 2009-10-29 |
JP4688681B2 (ja) | 2011-05-25 |
EP1698339A4 (en) | 2009-06-17 |
US20080306080A1 (en) | 2008-12-11 |
HK1098378A1 (en) | 2007-07-20 |
TW200522962A (en) | 2005-07-16 |
CA2549672C (en) | 2010-06-22 |
JPWO2005063250A1 (ja) | 2007-07-19 |
IL176473A0 (en) | 2006-10-05 |
RU2356555C2 (ru) | 2009-05-27 |
AU2004308806A1 (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2733440C (en) | Respiratory disease treatment | |
TW201434469A (zh) | 肺部疾病之治療法 | |
WO2010150014A1 (en) | 5r- 5 -deuterated glitazones for respiratory disease treatment | |
PT735877E (pt) | Compostos de 6-(2-imidazolinilamino)quinoxalina uteis como agonistas do receptor alfa-2 adrenergico | |
JPH09507219A (ja) | α−2−アドレノセプター作動剤として有用な7−(2−イミダゾリニルアミノ)キノリン化合物 | |
EP3554503B1 (en) | Inhibitors of bromodomain-containing protein 4 (brd4) | |
JPWO2004096274A1 (ja) | 気道内投与剤 | |
CA2120319C (en) | Pharmaceutical for the treatment of skin disorders | |
WO2005063250A1 (ja) | 好中球増多抑制剤 | |
WO2005074938A1 (ja) | 血管内膜肥厚抑制薬 | |
JP6275517B2 (ja) | Il−2産生抑制 | |
EP1307202A1 (en) | Method for the treatment of overactive bladder | |
WO1993023043A1 (en) | Agent for increasing somatostatin or for inhibiting decrease of somatostatin | |
JP2001500526A (ja) | 粘液溶解剤としての2−メチル−チアゾリジン−2,4−ジカルボン酸の使用 | |
PT1685849E (pt) | Inibidores de pde4 para o tratamento da cistite intersticial | |
MXPA06007434A (en) | Neutrophilia inhibitor | |
CN114040913A (zh) | 哒嗪酮trpc5抑制剂的喷雾干燥制剂 | |
WO2003008396A1 (fr) | Derive d'oxazine actif sur le plan optique | |
CN111511359A (zh) | 非甾体选择性糖皮质激素受体激动调节剂(segram)及其用途 | |
JP2004002256A (ja) | 光学活性オキサジン誘導体 | |
WO2004005259A1 (ja) | 置換ヒドロキシピリジン化合物のドラッグデリバリーシステムおよび置換ヒドロキシピリジン化合物の抱合体 | |
US20050222234A1 (en) | Mucin production inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480038158.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004807556 Country of ref document: EP Ref document number: 2004308806 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1600/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005516599 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2549672 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 176473 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007117806 Country of ref document: US Ref document number: 10584222 Country of ref document: US Ref document number: 1020067012723 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/007434 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2004308806 Country of ref document: AU Date of ref document: 20041222 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004308806 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006127040 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004807556 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067012723 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0417200 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10584222 Country of ref document: US |